[Equity Joint Venture Contract for the establishment of Sinovac (Dalian) Vaccine Technology Co., Ltd. i Table of Contents Chapter I The Parties 1 Chapter II Establishment of Joint Venture 1 Chapter III Purpose, Business Scope and Size 2 Chapter IV Aggregate Investment and Registered Capital 2 Chapter V Contribution Proportion and Deadline of the Parties 2 Chapter VI Responsibilities of] [MEMORANDUM This Memorandum is made on 22 November 2009: BETWEEN: 1. Dalian Jingang Group Co., Ltd. , with its legal address at No. 59, Liaohe Middle Road, Dalian 2. Sinovac Biotech (Hong Kong) Ltd. , a limited liability company duly incorporated and validly existing under the laws of the Hong Kong Special Administrative Region, the People’s Republic of China (hereinafter] [EQUITY INTEREST TRANSFER AGREEMENT BY AND BETWEEN DALIAN JINGANG GROUP CO., LTD. AND SINOVAC (HONG KONG) BIOTECH LTD. IN RESPECT OF 25% EQUITY INTEREST OF December 17, 2009 This Agreement is made on BETWEEN: 1. Dalian Jingang Group Co., Ltd., a limited liability company organized and existing under the laws of the People’s Republic of China (hereinafter referred to as] [Sinovac Announces Recent Developments BEIJING, January 20, 2010 — Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading China-based vaccine manufacturer, today announced the following recent developments. Dalian Joint Venture Acquisition of Buildings and Land Sinovac is in advanced negotiations for the acquisition of buildings, land use rights and utility facilities for a total consideration of approximately RMB120] [01 - 32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China Form 20-F x Form 40-F o o o Incorporation by Reference 2]

[Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities -Sinovac to Own 55% in Joint Venture by Year End 2010- BEIJING, Nov. 25 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines, announced today that it executed a joint venture (JV) agreement to establish Sinovac (Dalian) Vaccine Technology Co., Ltd. (Sinovac Dalian).] [01 - 32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]

[Sinovac Reports Unaudited Third Quarter 2009 Financial Results - Conference call scheduled Monday, November 16, 2009 at 9:00 a.m. ET - BEIJING, Nov. 15 /PRNewswire-Asia/ — Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines, announced today its unaudited financial results for the three-month and nine-month periods ended September 30, 2009. Financial Highlights · Sales for the] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]